Randomized, controlled trial to assess the safety and efficacy of odanacatib in the treatment of men with osteoporosis

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

DOI

  • N Binkley, University of Wisconsin School of Medicine and Public Health
  • ,
  • E Orwoll, Oregon Hlth & Sci Univ, Oregon University System, Oregon Health & Science University, Dept Obstet & Gynecol
  • ,
  • R Chapurlat, Université de Lyon, CREATIS, Université Lyon 1
  • ,
  • B L Langdahl
  • B B Scott, Merck & Co., Inc., Kenilworth
  • ,
  • H Giezek, MSD Europe Inc., Brussels, Belgium.
  • ,
  • A C Santora, Merck & Co., Inc., Kenilworth

Odanacatib (ODN) was investigated as an osteoporosis treatment in 292 men. Compared with placebo, odanacatib improved bone mineral density and led to sustained bone resorption decreases while producing relatively little bone formation reduction that leveled off with time. However, increased risk of stroke in another study stopped further odanacatib development.

INTRODUCTION: ODN, a selective oral cathepsin K inhibitor, was in development for osteoporosis treatment. This phase 3, double-blind, randomized, placebo-controlled, 24-month study investigated ODN safety and efficacy in men with osteoporosis.

METHODS: Men with idiopathic osteoporosis or osteoporosis due to hypogonadism and a lumbar spine or hip (total hip [TH], femoral neck [FN], or trochanter) bone mineral density (BMD) T-score of ≤ - 2.5 to ≥ - 4.0 without prior vertebral fracture or ≤ - 1.5 to ≥ - 4.0 with one prior vertebral fracture were randomized (1:1) to once-weekly ODN 50 mg or placebo. All received 5600 IU vitamin D3 weekly and calcium supplementation as needed (≥ 1200 mg daily). The primary efficacy outcome was changed from baseline in lumbar spine BMD versus placebo.

RESULTS: Overall, 292 men, mean age 68.8 years, were randomly assigned to ODN or placebo. Versus placebo, ODN increased BMD from baseline at the lumbar spine, TH, FN, and trochanter by 5.6%, 2.0%, 1.7%, and 2.1%, respectively (all p < 0.01), and decreased uNTx/Cr (68%, p < 0.001), sCTx (77%, p < 0.001), sP1NP (16%, p = 0.001), and sBSAP (8%, p = 0.019). The between-group bone formation marker decrease peaked at 3 months, then returned toward baseline. The safety profile, including cardiovascular events, was similar between groups.

CONCLUSION: Though a promising osteoporosis therapy for men, ODN development was discontinued due to increased risk of stroke in the LOFT phase 3 trial.

TRIAL REGISTRATION: Clinicaltrials.gov NCT01120600 (registered May 11, 2010).

OriginalsprogEngelsk
TidsskriftOsteoporosis International
Vol/bind32
Nummer1
Sider (fra-til)173-184
Antal sider12
ISSN0937-941X
DOI
StatusUdgivet - jan. 2021

Se relationer på Aarhus Universitet Citationsformater

ID: 207978640